Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flow from operating activities:
Net loss	$ (111,966)	$ (15,041)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	4,685	4,603
Non cash lease expense	(40)	(25)
Provision for doubtful accounts	374	3
Goodwill impairment	29,633	0
Change in fair value of warrant liabilities	(1,601)	(22,280)
Stock-based compensation expense	7,844	6,951
Change in fair value of contingent consideration	(104,339)	(40,198)
Acquired in-process research and development	3,000
Issuance of common stock for stem-cells to be used in research and development	1,000
Discounts arising from RWI loan arrangement	2,151
Change in fair value of contingent stock consideration	(120)	611
Change in fair value of debt	2,357	0
Other, net	876	(212)
Changes in assets and liabilities:
Accounts receivable	1,266	(1,191)
Inventory	(2,820)	(14,692)
Prepaid expenses and other assets	2,981	511
Accounts payable	6,043	1,020
Accrued expenses and other liabilities	645	5,751
Accrued R&D Software	23,917	3,328
Right-of-use assets and lease liabilities	117	128
Deferred revenue	175	162
Net cash used in operating activities	(26,022)	(70,571)
Cash flow from investing activities:
Capital expenditures	(240)	(2,894)
Purchase of acquired in-process research and development	(3,000)
Net cash used in investing activities	(3,240)	(2,894)
Cash flow from financing activities:
Proceeds from RWI senior secured bridge loan and warrants	12,375
Principal payments of short-term debt	(16,811)
Proceeds from issuance of senior secured bridge loan and warrants	4,994
Proceeds from the exercise of stock options	304	248
Proceeds from the exercise of warrants		46,489
Proceeds from PIPE financing	12,750	30,000
Proceeds from the sale of common stock in ATM offering	136
Tax withholding on vesting of restricted stock units	(86)
Proceeds from registered direct offering	6,000
Payments of PIPE and other issuance costs	(1,293)	(2,523)
Net cash provided by financing activities	18,369	74,214
Net (decrease) increase in cash, cash equivalents and restricted cash	(10,893)	749
Cash, cash equivalents and restricted cash at beginning of period	28,802	52,076
Cash, cash equivalents and restricted cash at end of period	17,909	52,825
Supplemental disclosure of cash flow information:
Cash paid for interest	1,073
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	(1,010)	(953)
Issuance of warrants on senior secured bridge loans	2,002
Common stock issued for short-term debt conversion	3,792
PIPE related costs included in accrued expenses	(69)	(81)
Interest accrued on senior secured loans within long-term debt	(307)
Reclassification of option liabilities to equity		$ 441
IPR&D
Adjustments to reconcile net loss to net cash used in operations:
Impairment of intangible assets, excluding goodwill	$ 107,800